Bone destruction
Also known as: Lytic lesion / Osteolysis / Resorption bone increased
Drug | Drug Name | Drug Description |
---|---|---|
DB06643 | Denosumab | A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB06643 | Denosumab | Tumor necrosis factor ligand superfamily member 11 | target |
Drug | Drug Name | Phase | Status | Count |
---|